Location: St. Regis San Francisco
Monday May 9, 2011
Breakfast & Registration
Welcome: The Global Neurotech Industry 2011
Managing Director, NeuroInsights
Investing in Neurotech Panel
A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?
Moderator: Bruce Leuchter
Director, Clinical Neuropsychiatry & Neurostimulation Therapies, Weill Cornell Medical College
Managing Director, MPM Capital
Principal, Third Rock Ventures
Managing Director, Versant Ventures
Partner, Prospect Venture Partners
Visium Asset Management
Networking and Refreshment Break
Beyond the BBB: Gene Therapy, Cell Implants and Drug Delivery
Companies present novel approaches for delivering new therapeutics for the brain and nervous system including gene therapy, cell therapy, protein conjugates and neurodevice innovations.
Session Chair: John Reher
Partner, Brain Trust Accelerator Fund
Chairman & CEO, MedGenesis Therapeutix
Executive Vice President and COO, NsGene
Alzheimer's and MCI
As the population ages, the market for Alzheimer's and cognitive disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?
Session Chair: Stephen Knight
Managing Partner, Fidelity Bioscience
CEO, EnVivo Pharmaceuticals
CEO, Satori Pharmaceuticals
CEO, Neuronix Medical
CEO, Functional Neuromodulation, Inc.
Internal and External Research & Development
What is in the pipeline at Big Pharma, Big Biotech and Big Medtech? Where are companies focusing internal versus external resources? What opportunities exist for research and development collaborations?
Session Chair: Liam Ratcliffe
General Partner, New Leaf Venture Partners
VP of Research and Business Development, Medtronic Neuromodulation
VP and Head External Innovation for Neuroscience, Johnson & Johnson
Vice President, Head of Neuroscience Clinical Research, Pfizer
Head of Neuroscience Partnering, Genentech
Networking and Refreshment Break
Orphan Disorders: ALS, Huntington's, Friedreich's Ataxia and more
With regulatory and reimbursement approvals becoming more difficult, the profile of orphan disorders is on the rise. Companies have now shown that premium pricing for orphan disorders can propagate a highly successful business model. What new treatments are on the horizon?
Session Chair: Jennifer King
Senior Director, Scientific Licensing and Business Development, Shire
CEO, Afraxis & Managing Director, Avalon Ventures
CEO, Ariel Pharmaceuticals
CEO, Synapse Biomedical
New Business Models in Neurotechnology
With venture capital steering away from long term and risky investments, neurosoftware, neurofeedback, neuromarketing and other new business models represent far lower risk and faster times to market. What winning strategies are emerging in brain fitness, sleep management, neuroplasticity, and human performance?
Session Chair: Roger Quy
General Partner, Technology Partners
CEO, Posit Science
CEO and Co-Founder, Advanced Brain Monitoring
Tuesday May 10, 2011
Continental Breakfast & Registration
Partnering and Licensing in Neurotech Panel
Big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in strategic alliances and inlicensing? With cutbacks in internal neuropharma R&D can we expect more partnering deals? Which companies are active in outlicensing deprioritized programs? What are priority indications and requirements for licensing deals? Where are the opportunities for neurodevice partnerships and where are the major players focusing their attentions? With big pharma paying more attention to neurodiagnostics, what kinds of deals and partnerships can we expect in 2011?
Moderator: Christine de los Reyes
Managing Director, BiotechPartnering Solutions
Vice President of Intellectual Property & Business Development, St. Jude Medical
Director, Scientific Licensing, Corporate Business Development & Strategy
H. Lundbeck A/S
VP Licensing, Neuroscience and EMEA, Johnson & Johnson
Global Head, Business Development, Aging, Sanofi-Aventis
Alethia de Leon
Head of Search & Evaluation, Neuroscience and Ophthalmics, Global BD&L, Novartis
Frontiers in Neurotechnology
In this session we will hear from companies on the cutting edge. Novel neurostimulation devices are being developed for new markets including sensory disorders, hypertension, obesity, sleep apnea, neuroimmunology and many others. New technology developed in other fields is yeilding benefits in neurodiagnostics. Exciting new platforms leveraging cutting edge techniques are being used for drug discovery. Don't miss this preview of next generation products and companies.
Session Chair: Vincent Kim
Partner, Aberdare Ventures
CEO, Circuit Therapeutics
Founder and CEO, DiLorenzo Biomedical
Business Development, Heidelberg Engineering
CEO, Stimwave Technologies
Next Generation Psychiatry
Schizophrenia, anxiety, depression, addiction and other psychiatric illnesses represent a large portion of the neurotech market. What are the most promising next generation treatments? How will devices and diagnostics change the treatment landscape?
Session Chair: Manuel Lopez-Figueroa
Vice President, Bay City Capital
CEO, Euthymics Bioscience
President & CEO, NextWave Pharmaceuticals
CEO, Ridge Diagnostics
Partnering Lunch sponsored by The Neurotechnology Industry Organization
Strategies for CNS Drug and Device Development
Through case studies, drug and device companies will discuss lessons learned and current issues in discovery, animal models, clinical trial design, regulatory hurdles, reimbursement challenges, financing and partnering. Regulatory and clinical experts will join the discussion to highlight changes at the FDA and strategies for changing current paradigms in CNS treatment development.
Session Chair: Michael Grey
Venture Partner, Pappas Ventures
Sr. Director, Business & Commercial Development, Targacept
Vice President, Global Medical Therapeutic Head, CNS, Quintiles
Partner K&L Gates, NIO Regulatory Counsel
Pain, Epilepsy, & Migraine
Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in treatment resistant populations for epilepsy and neuropathic pain.
Session Chair: Joyce Cramer
Executive Director: Epilepsy Therapy Project
Chief Clinical Development Officer, Marinus Pharmaceuticals
President and CEO, NeuroSigma
President and CEO, Spinal Modulation
NIO Working Group
An overview and participant discussion of current and future congressional, FDA, and CMS initiatives to advance neurotech.
Executive Director, Neurotech Industry Organization
Director of Public Policy, Neurotech Industry Organization
Partner, K&L Gates, NIO Public Policy Counsel